Avalo Therapeutics, Inc.
Clinical-stage biotech developing treatments for immune-mediated inflammatory diseases.
AVTX | US
Overview
Corporate Details
- ISIN(s):
- US05338F1084 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 1500 LIBERTY RIDGE DRIVE, 19087 WAYNE
- Website:
- https://www.avalotx.com/
Description
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for immune-mediated inflammatory diseases. The company's strategy is centered on advancing novel therapies that target the interleukin-1 beta (IL-1β) pathway. Its lead asset, AVTX-009, is an IL-1β monoclonal antibody currently in a Phase 2 clinical trial for the treatment of hidradenitis suppurativa (HS). Avalo Therapeutics is also exploring the application of its IL-1β-based approach for other prevalent inflammatory conditions with significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Avalo Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Avalo Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Avalo Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
